The Human Antibody Core Facility is based on a technology that was developed at the Oklahoma Medical Research Foundation. The technology facilitates the production of fully human, full-length, antigen-specific monoclonal antibodies. The process can be completed in as little as 28 days post infection or immunization and creates full-length, properly paired antibodies of any desired IgG subclass. As a core facility, we have produced human monoclonals for a variety of purposes including novel diagnostics, passive immunotherapeutics and most importantly, understanding human immune responses to vaccination. We currently have a library of over nine hundred monoclonal antibodies. Known specificities include seasonal and pandemic H1N1, H3N2 and B influenza strains, S. pneumoniae capsular polysaccharide, rabies and vaccinia virus, and anthrax protective antigen (PA). In particular, our antibodies to anthrax protective antigen (PA), derived from an individual vaccinated with Anthrax Vaccine Absorbed (AVA), were carefully characterized, and two antibodies which bound to complex conformational epitopes of PA were shown to be protective against lethal toxin challenge both in vitro and in vivo. Our core facility produced these anti-PA monoclonals with previous funding as a member of the Cooperative Centers for Human Immunology during the last six years.
We will provide this technology to the U19 projects for a variety of needs, including reagents to explore peptidoglycan (PGN)-triggered inflammation, and screening our current library of antibodies for antinucleosome specificities for experiments involving B. anthracis sepsis. This technology has been valuable during the last funding period and continues to be strongly applicable to the projects in the current proposal, as it will be instrumental in developing novel scientific tools that will facilitate the project goals.
|Liu, Ke; Kurien, Biji T; Zimmerman, Sarah L et al. (2016) X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and SjÃ¶gren's Syndrome. Arthritis Rheumatol 68:1290-300|
|Garman, Lori; Smith, Kenneth; Muns, Emily E et al. (2016) Unique Inflammatory Mediators and Specific IgE Levels Distinguish Local from Systemic Reactions after Anthrax Vaccine Adsorbed Vaccination. Clin Vaccine Immunol 23:664-71|
|Hu, Zihua; Jiang, Kaiyu; Frank, Mark Barton et al. (2016) Complexity and Specificity of the Neutrophil Transcriptomes in Juvenile Idiopathic Arthritis. Sci Rep 6:27453|
|Devera, T Scott; Lang, Gillian A; Lanis, Jordi M et al. (2016) Memory B Cells Encode Neutralizing Antibody Specific for Toxin B from the Clostridium difficile Strains VPI 10463 and NAP1/BI/027 but with Superior Neutralization of VPI 10463 Toxin B. Infect Immun 84:194-204|
|McMurtrey, Curtis; Trolle, Thomas; Sansom, Tiffany et al. (2016) Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove. Elife 5:|
|Wu, Wenxin; Zhang, Wei; Booth, J Leland et al. (2016) Human primary airway epithelial cells isolated from active smokers have epigenetically impaired antiviral responses. Respir Res 17:111|
|Booth, J Leland; Duggan, Elizabeth S; Patel, Vineet I et al. (2016) Bacillus anthracis spore movement does not require a carrier cell and is not affected by lethal toxin in human lung models. Microbes Infect 18:615-626|
|Smith, Kenneth; Shah, Hemangi; Muther, Jennifer J et al. (2016) Antigen nature and complexity influence human antibody light chain usage and specificity. Vaccine 34:2813-20|
|Patel, Vineet Indrajit; Metcalf, Jordan Patrick (2016) Identification and characterization of human dendritic cell subsets in the steady state: a review of our current knowledge. J Investig Med 64:833-47|
|Kovats, S; Turner, S; Simmons, A et al. (2016) West Nile virus-infected human dendritic cells fail to fully activate invariant natural killer T cells. Clin Exp Immunol 186:214-226|
Showing the most recent 10 out of 105 publications